Get the Stockscreener App
91.00
2.62%
2.32
After Hours:
91.39
0.39
+0.43%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $91.00, with a volume of 7.40M.
It is up +2.62% in the last 24 hours and up +9.35% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$88.68
Open:
$89.34
24h Volume:
7.40M
Relative Volume:
1.53
Market Cap:
$282.23B
Revenue:
$58.07B
Net Income/Loss:
$9.40B
P/E Ratio:
30.22
EPS:
3.0113
Net Cash Flow:
$8.49B
1W Performance:
+2.13%
1M Performance:
+9.35%
6M Performance:
+30.60%
1Y Performance:
+41.61%
1-Day Range:
$89.34
$91.91
1-Week Range:
$88.41
$91.91
52-Week Range:
$61.24
$91.91
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
91.00 | 274.96B | 58.07B | 9.40B | 8.49B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca strengthens its manufacturing footprint in the US with a $2bn investment - MarketScreener
Why AstraZeneca Stock Bumped Higher Today - Yahoo Finance
AstraZeneca unveils USD2 billion manufacturing investment in Maryland - MarketScreener
AstraZeneca (AZN) to Invest $2B in U.S. Production Expansion - GuruFocus
AstraZeneca expands U.S. production footprint with $2B investment in Maryland - MSN
AstraZeneca to Invest $2 Billion to Expand Maryland Manufacturing Footprint - MarketScreener
AstraZeneca (AZN) Plans $2 Billion Expansion in Maryland - GuruFocus
AstraZeneca announces $2B investment in Maryland (AZN:NASDAQ) - Seeking Alpha
AstraZeneca to invest $2B in Maryland facilities - breakingthenews.net
AstraZeneca to invest $2 billion expanding Maryland manufacturing sites By Investing.com - Investing.com UK
AstraZeneca Plans $2 Billion Manufacturing Investment in Maryland, Supporting 2,600 Jobs and Catalyzing Economic Growth - MarketScreener
AstraZeneca to invest $2 billion as part of US manufacturing push - MarketScreener
AstraZeneca Plans $2 Bln Manufacturing Investment In Maryland - TradingView
AstraZeneca to invest $2B in Maryland manufacturing expansion, creating 300 jobs - The Business Journals
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo - Finviz
What's Driving the Market Sentiment Around AstraZeneca PLC? - Benzinga
Will AstraZeneca PLC Depositary Receipt continue its uptrend2025 Volatility Report & Weekly High Momentum Picks - newser.com
Can AstraZeneca PLC (Common Stock) (ZEGA) stock surprise with quarterly resultsIPO Watch & Daily Profit Maximizing Tips - newser.com
What drives AstraZeneca PLC ZEG stock priceSwing Trading Ideas & Exceptional Growth Portfolio - earlytimes.in
AstraZeneca (AZN) Partners in $120M Pharmaceutical Training Init - GuruFocus
AstraZeneca's Alexion gets FDA approval for Koselugo (AZN:NASDAQ) - Seeking Alpha
AstraZeneca receives US FDA approval for Koselugo in adults with NF1 - Investing.com UK
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca PLCKoselugo (selumetinib) approved in the US - Research Tree
What insider trading reveals about AstraZeneca PLC Depositary Receipt stockWatch List & Trade Opportunity Analysis Reports - newser.com
Will AstraZeneca PLC (Common Stock) (ZEGA) stock deliver compounding returnsExit Point & Daily Stock Trend Reports - newser.com
AstraZeneca receives FDA approval for expanded Koselugo usage - Sharecast.com
AstraZeneca says Koselugo (Selumetinib) approved in the US - MarketScreener
AstraZeneca Unit's Neurofibromatosis Treatment Receives US Approval - MarketScreener
How AstraZeneca PLC (ZEG) stock valuation compares with sector2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
Burning Rock Reports Third Quarter 2025 Financial Results - GlobeNewswire Inc.
Is AstraZeneca PLC (ZEG) stock positioned for digital growth era - newser.com
Is Precidian ETFs Trust AstraZeneca PLC stock safe for risk averse investorsWeekly Trend Summary & Target Return Focused Picks - newser.com
Can Precidian ETFs Trust AstraZeneca PLC stock deliver double digit returnsMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
AstraZeneca PLC Depositary Receipt stock chart pattern explainedTrade Risk Assessment & Fast Moving Stock Trade Plans - newser.com
How AstraZeneca PLC (Common Stock) (ZEGA) stock compares with top peers2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
Why AstraZeneca PLC (Common Stock) (ZEGA) stock is favored by hedge funds2025 Trading Recap & Fast Exit and Entry Strategy Plans - newser.com
What valuation multiples suggest for AstraZeneca PLC Depositary Receipt stock2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Is Precidian ETFs Trust AstraZeneca PLC stock a top dividend aristocrat candidate2025 Top Decliners & Step-by-Step Swing Trade Plans - newser.com
Using fundamentals and technicals on AstraZeneca PLC Depositary ReceiptEarnings Summary Report & Weekly Stock Performance Updates - newser.com
AstraZeneca Wins FDA Approval for Selumetinib in Adult NF1 Patients - MarketScreener
AstraZeneca (AZN) Gains FDA Approval for Koselugo in Neurofibrom - GuruFocus
AstraZeneca (AZN) Gains FDA Approval for Koselugo in Adult Treat - GuruFocus
AstraZeneca trades near highs after robust financials drive institutional flows - Traders Union
Will Precidian ETFs Trust AstraZeneca PLC stock deliver compounding returnsJuly 2025 Macro Moves & Weekly High Return Opportunities - newser.com
Can AstraZeneca PLC Depositary Receipt stock sustain revenue growth2025 Top Decliners & Reliable Price Breakout Alerts - newser.com
Will AstraZeneca PLC Depositary Receipt stock benefit from sector rotationPortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Is AstraZeneca PLC (ZEG) stock undervalued historicallyWeekly Profit Report & Community Driven Trade Alerts - newser.com
Published on: 2025-11-18 17:18:56 - newser.com
What market sentiment indicators show for Precidian ETFs Trust AstraZeneca PLC stock2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
How AstraZeneca PLC (ZEG) stock trades under stagflationPortfolio Gains Summary & Risk Managed Investment Entry Signals - newser.com
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):